US Onychomycosis Market Size By Product (Antifungal Medications, Non-Pharmacological Products), By Treatment (Pharmacological, Non-Pharmacological), By Geographic Scope And Forecast

US Onychomycosis Market Size And Forecast

US Onychomycosis Market size was valued at USD 3.69 Billion in 2023 and is projected to reach USD 6.72 Billion by 2031, growing at a CAGR of 8.60% from 2024 to 2031.

• Onychomycosis refers to a fungal infection of the toenails or fingernails. It is a common condition affecting a significant portion of the population, especially the elderly and individuals with compromised immune systems.
• The US Onychomycosis Market represents a substantial segment within the dermatology and pharmaceutical industries. It encompasses the sale of medications, topical treatments, and medical devices aimed at diagnosing and treating nail fungal infections.
• Onychomycosis is prevalent in the US, with estimates suggesting that millions of Americans are affected by this condition. It is more common in older adults but can occur in people of all ages.
• Onychomycosis is primarily caused by dermatophyte fungi, including species like Trichophyton rubrum and Trichophyton mentagrophytes. Other factors, such as poor foot hygiene, trauma to the nail, and underlying health conditions like diabetes, contribute to its development.
• Symptoms of onychomycosis include thickened nails, discoloration (typically yellow or brown), brittle or crumbly texture, and sometimes a foul odor. In severe cases, the infection may cause pain and difficulty walking or using the affected appendage.
• Diagnosis of onychomycosis involves clinical examination, nail scraping for microscopic examination or fungal culture, and sometimes additional tests like polymerase chain reaction (PCR) assays. Dermatologists and podiatrists commonly diagnose and treat this condition.
• Treatment of onychomycosis typically involves topical or oral antifungal medications. Topical treatments include medicated nail polishes or creams, while oral medications like terbinafine or itraconazole are prescribed for more severe cases. In some instances, surgical intervention or laser therapy may be necessary.

US Onychomycosis Market Dynamics

The key market dynamics that are shaping the US Onychomycosis Market include

Key Market Drivers

• High PrevalenceThe high prevalence of onychomycosis in the US population is a significant driver of the market. Millions of Americans are affected by nail fungal infections, leading to a constant demand for effective treatments.
• Aging PopulationThe aging population, particularly individuals over the age of 60, is more susceptible to onychomycosis due to factors such as reduced blood circulation, weakened immune systems, and slower nail growth. As the population ages, the incidence of onychomycosis is expected to rise, driving market growth.
• Increasing AwarenessGrowing awareness among both patients and healthcare providers about onychomycosis and its consequences has led to higher rates of diagnosis and treatment seeking. This increased awareness contributes to market expansion as more individuals seek medical intervention for their nail fungal infections.
• Advancements in TreatmentOngoing research and development efforts have led to the introduction of new and improved treatment options for onychomycosis. Innovations in antifungal medications, topical formulations, and medical devices, such as laser therapy, offer more effective and convenient solutions for patients, driving market growth.
• Technological AdvancementsTechnological advancements in diagnostic methods, such as polymerase chain reaction (PCR) assays and high-resolution imaging techniques, enable more accurate and timely diagnosis of onychomycosis. This facilitates appropriate treatment selection and contributes to market expansion.
• Increasing Healthcare ExpenditureThe rise in healthcare expenditure in the US, coupled with expanding insurance coverage for dermatological conditions, ensures greater accessibility to onychomycosis treatments for patients. This financial support drives market growth by encouraging treatment-seeking behavior.

Key Challenges

• Treatment AdherenceOne of the primary challenges in managing onychomycosis is ensuring patient adherence to treatment regimens. Oral antifungal medications often require prolonged courses of therapy, and topical treatments may need to be applied consistently over several months. Poor adherence can lead to treatment failure or recurrence of the infection.
• High Recurrence RatesOnychomycosis has high recurrence rates, with a significant proportion of patients experiencing re-infection even after successful treatment. This poses a challenge for healthcare providers in achieving long-term resolution of the condition and may necessitate repeated treatment cycles.
• Antifungal ResistanceThe emergence of antifungal resistance poses a significant challenge in the management of onychomycosis. Prolonged use of antifungal medications, particularly in cases of recurrent infections, can contribute to the development of resistant fungal strains, limiting treatment options and efficacy.
• Diagnostic LimitationsDiagnosis of onychomycosis can be challenging due to the variability in clinical presentation and the limitations of current diagnostic methods. Nail sampling techniques may yield false-negative results, leading to delayed or missed diagnoses. Improving diagnostic accuracy is essential for timely and effective management of the condition.
• Cost of TreatmentThe cost of onychomycosis treatment, particularly for oral antifungal medications, can be substantial for patients, especially those without adequate insurance coverage. High out-of-pocket expenses may deter some individuals from seeking or adhering to treatment, exacerbating the burden of the condition.

Key Trends

• Advancements in Treatment ModalitiesThe US Onychomycosis Market is witnessing advancements in treatment modalities, including the development of novel antifungal medications, topical formulations, and medical devices. These innovations aim to improve treatment efficacy, reduce treatment duration, and enhance patient convenience.
• Topical TherapiesThere is a growing trend towards the use of topical therapies for onychomycosis, including medicated nail lacquers, gels, and creams. These formulations offer targeted delivery of antifungal agents to the site of infection and are often preferred for mild to moderate cases or as adjunctive therapy to oral medications.
• Oral Antifungal AgentsOral antifungal agents, such as terbinafine and itraconazole, remain a cornerstone of onychomycosis treatment, particularly for severe or resistant infections. The market is witnessing the development of new formulations and dosing regimens to enhance treatment outcomes and minimize adverse effects.
• Laser TherapyLaser therapy for onychomycosis has gained popularity in recent years as a non-invasive alternative to traditional treatments. Laser devices target fungal pathogens within the nail bed, offering potential benefits such as improved efficacy, shorter treatment duration, and minimal side effects. The market is seeing increased adoption of laser therapy systems by dermatologists and podiatrists.
• Combination TherapiesCombination therapies involving the use of oral and topical antifungal agents, along with adjunctive treatments such as debridement or nail avulsion, are being explored for the management of onychomycosis. These multimodal approaches aim to enhance treatment efficacy, reduce recurrence rates, and improve patient outcomes.

US Onychomycosis Market Regional Analysis

Here is a more detailed regional analysis of the US Onychomycosis Market

North America

• North America is significantly dominating the onychomycosis market and is expected to continue its growth throughout the forecast period, owing to several variables.
• Onychomycosis is highly prevalent in North America, with millions of cases reported annually. Factors such as the aging population, increased prevalence of diabetes, and lifestyle factors contribute to the high incidence of nail fungal infections in this region.
• North America boasts advanced healthcare infrastructure, including well-developed medical facilities, research institutions, and pharmaceutical companies. This infrastructure supports the diagnosis, treatment, and management of onychomycosis, ensuring access to state-of-the-art therapies and technologies.
• The pharmaceutical industry in North America is robust, with leading companies investing heavily in research and development of onychomycosis treatments. These companies develop and market a wide range of antifungal medications, topical formulations, and medical devices for the management of nail fungal infections.
• North America is at the forefront of technological advancements in healthcare, including diagnostic tools, treatment modalities, and medical devices. Innovations such as laser therapy for onychomycosis and molecular diagnostic tests have originated in this region, driving market growth and adoption.
• Compared to many other regions, North America has relatively high levels of access to healthcare services, including dermatologists, podiatrists, and specialized clinics. This accessibility ensures timely diagnosis and treatment of onychomycosis for patients across the socioeconomic spectrum.
• North America has one of the highest healthcare spending levels, with substantial investments in pharmaceuticals and medical technology. This financial investment supports research, innovation, and the widespread availability of onychomycosis treatments in the market.

Asia Pacific

• Asia Pacific is anticipated to be the fastest-growing region. Asia Pacific is home to a significant portion of the population, creating a large patient pool for onychomycosis treatments.
• Increasing awareness about nail fungal infections and their consequences is leading to higher rates of diagnosis and treatment-seeking behavior in the region.
• Urbanization and westernization of lifestyles in many Asian countries have led to an increase in risk factors for onychomycosis, such as wearing closed-toe shoes and using communal bathing facilities.
• Improvements in healthcare infrastructure and access to medical services are facilitating the diagnosis and treatment of onychomycosis in previously underserved areas.
• Economic development in countries across the Asia Pacific region is driving higher healthcare spending and increasing the affordability of onychomycosis treatments for patients.
• Pharmaceutical companies are increasingly investing in research and development of onychomycosis treatments tailored to the needs of Asian populations, leading to the introduction of new and improved therapies.
• Advancements in medical technology and treatment modalities, such as laser therapy and topical formulations, are expanding the range of options available for managing onychomycosis in the Asia Pacific region.
• Government initiatives aimed at improving public health and increasing access to healthcare services are contributing to the growth of the onychomycosis market in Asia Pacific.

US Onychomycosis MarketSegmentation Analysis

The US Onychomycosis Market is Segmented on the basis of Product, Treatment, And Geography.

US Onychomycosis Market, By Product

• Antifungal Medications
• Non-Pharmacological Products
• Nail Care Products

Based on Product, the market is segmented into Antifungal Medications, Non-Pharmacological Products, and Nail Care Products. The nail care segment is poised to emerge as a dominant force in the market, driven by a rising preference for topical nail lacquers over antifungal drugs. Additionally, the tablet segment may experience growth, spurred by governmental initiatives promoting the adoption of generic drugs.

US Onychomycosis Market, By Treatment

• Pharmacological
• Non-Pharmacological

Based on Treatment, the market is segmented into Pharmacological, and Non-Pharmacological. The pharmacological segment is showing significant growth int the treatment category. Both topical and oral medications are viable options for treating fungal nail infections. The primary objective of therapy, as confirmed by microscopy and culture, is the complete eradication of the organism from the body. Among the oral medications commonly utilized for onychomycosis treatment are griseofulvin, terbinafine, itraconazole, and ketoconazole. However, oral antifungal medications like terbinafine are associated with longer treatment durations and a higher incidence of side effects compared to topical antifungal drugs.

Key Players

The “US Onychomycosis Market” study report will provide valuable insight emphasizing the market. The major players in the market are Novartis AG, Johnson & Johnson, Pfizer Inc., Galderma S.A., Bayer AG, Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, Merz Pharma GmbH & Co. KGaA, Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players.

Key Developments

• In April 2021, Alembic Pharmaceuticals Limited disclosed that its joint venture, Aleor Dermaceuticals Limited (Aleor), had secured tentative approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) concerning Efinaconazole Topical Solution, indicated for the treatment of toenail onychomycosis.
• In February 2021, Lupin Limited obtained approval from the US Food and Drug Administration (FDA) for its Tavaborole Topical Solution, designed for the management of onychomycosis.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.